SAN DIEGO, July 25, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the appointment of Gregory D. Gorgas as Senior Vice President, Commercial.
Mr. Gorgas brings more than 25 years of experience in drug product commercialization, with an emphasis in launching new products, building commercial infrastructure and leading start-up operations. He was a key contributor to the blockbuster success of Rituxan® while at Biogen Idec, where most recently he led global marketing for the oncology franchise.
"After consulting with ADVENTRX for over 18 months, I have deep familiarity with the company and its product candidates and believe in the promise and commercial potential of Exelbine," said Mr. Gorgas. "I'm thrilled to join the ADVENTRX team and look forward to making Exelbine available to patients, should it be approved."
"Greg's first-hand experience successfully launching four first-in-class products and strong relationships in the oncology community make him a great addition to our team. Importantly, his understanding of the multi-source marketplace will prove valuable as we continue to prepare for the launch of Exelbine," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates. The Company's current lead product candidates are Exelbine and ANX-514, novel emulsion formulations of currently marketed chemotherapy drugs, and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis. More information can be found on the Company's web site at
|SOURCE ADVENTRX Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved